Ovarian cycle

Reading File

Finding Sources

Searching Images

ovarian cycle follicular development ovulation corpus luteum diagram

This composite figure illustrates transvaginal ultrasonography (TVUS) findings of the uterus and ovaries throughout the menstrual cycle, organized into three phases: early follicular (a-c), late follicular (d-f), and post-ovulatory luteal (g-i). In the early follicular phase, the endometrium is thin and homogenous (blue arrows), with multiple small antral follicles (red arrows) visible in the ovary. The late follicular phase displays a thickened endometrium with a characteristic 'triple-line' pattern (d) and a large, hypoechoic dominant follicle approximately 2 cm in diameter (f). The luteal phase shows a 'luteinized' endometrium with increased echogenicity (g) and the transformation of the dominant follicle into a corpus luteum (i), characterized by an inhomogenous internal structure and filament-like contents. Anechoic free fluid in the pelvis, indicative of recent ovulation, is highlighted by white arrows in the late follicular and luteal phase images. Schematic diagrams (b, e, h) provide anatomical context for the sonographic changes in endometrial morphology and ovarian follicle development.

This pathophysiology diagram illustrates the sequential stages of ovarian follicular development and the regulatory factors influencing the ovulation rate, using a murine model for context. The process initiates with primordial follicles, which undergo 'Activation' to become preantral follicles. These then mature into antral follicles, eventually culminating in ovulation. The Hypothalamic-Pituitary-Gonadal (HPG) axis is shown influencing the cycle through GnRH, which regulates LH and FSH, along with Progesterone (P4) involvement. Key regulatory pathways highlighted include 'Follicular survival,' which leads toward ovulation, and an opposing pathway for 'Follicular atresia.' The diagram maps specific molecular markers to the Diestrus and Estrus stages of the cycle. During Diestrus, follicular activation and survival are associated with Foxl2, Kit, Smad1, Lhcgr, Cxcr4, and Nos2. During Estrus, these processes involve Esr1, Fgf2, and Igfbp2. The educational focus is on the complex interplay between endocrine signaling and local gene expression that determines follicular fate and overall ovulation rate.

A multi-panel pathophysiology diagram illustrating the synchronous physiological changes during a standard 28-day human menstrual cycle. The top panel graphs gonadotropin levels, showing a sharp surge in Luteinizing Hormone (LH) and a moderate rise in Follicle-Stimulating Hormone (FSH) at day 14, correlating with the follicular phase, ovulation, and luteal phase stages. The corresponding follicular development shows the maturation of a primary follicle into a Graafian follicle, ovulation, and the formation of the corpus luteum and corpus albicans. The middle panel tracks plasma sex hormone levels, highlighting the mid-cycle peak of Estradiol (E2) and the post-ovulatory rise of Progesterone (P4). The bottom panel depicts endometrial morphology, transitioning from the menstrual phase to the proliferative and secretory phases. A green-shaded layer highlights the glycocalyx development, which thickens and becomes most prominent during the secretory phase under the influence of P4, before thinning during menstruation. The diagram demonstrates the hormonal regulation of the ovary and uterine lining for medical educational purposes.

A series of five transabdominal ultrasound images (A-E) illustrating various stages and pathologies of ovarian follicular development. (A) Shows a dominant, pre-ovulatory follicle on the left ovary, measuring approximately 3.39 x 3.73 cm, displaying a characteristic hypoechoic, fluid-filled center. (B) Displays a significantly enlarged dominant follicle (approximately 60 mm) that regressed without ovulating. (C) Depicts a corpus luteum (CL) characterized by a heterogeneous, more echogenic, and solid-appearing internal texture compared to fluid-filled follicles. (D) Illustrates a large hemorrhagic anovulatory follicle (HAF) with a complex internal architecture containing multiple hyperechoic fibrous or echogenic bands and septations. (E) Shows an unstimulated atretic follicle; a white arrow highlights a distinctive ultrasound sign of atresia where the granulosa cell layer has separated or lifted from the follicle wall. These images provide diagnostic criteria for monitoring ovulation induction, distinguishing between functional luteal tissue and anovulatory structures.

Reading File

Loading Image

Reading File

Loading Image

I now have comprehensive content from multiple authoritative textbooks. Let me compose a thorough, well-structured answer.

The Ovarian Cycle

The ovarian cycle is the monthly sequence of hormonal and structural changes in the ovary that culminates in the release of a mature oocyte and preparation of the endometrium for possible implantation. In women, it averages 28 days (range: 20-45 days) and runs from puberty (menarche) to menopause.

Overview of the Cycle: Two Phases

Phase	Days (approx.)	Dominant hormone	Key event
Follicular phase	1-13	Estrogen (estradiol)	Follicle growth and maturation
Ovulation	Day 14	LH surge	Oocyte released
Luteal phase	15-28	Progesterone + estrogen	Corpus luteum activity

Hormonal Control: The Hypothalamic-Pituitary-Ovarian Axis

The entire cycle is driven by:

GnRH (pulsatile) from the hypothalamus
FSH and LH (glycoproteins, MW ~30,000) from the anterior pituitary

At puberty, the pituitary begins secreting rising quantities of FSH and LH. Both bind to specific receptors on ovarian cells and act via cAMP, stimulating sex hormone synthesis. In the absence of gonadotropins, the ovaries remain dormant.

Menstrual cycle hormones, follicular development, and endometrial changes across 28 days

Phase 1: Follicular Phase (Days 1-13)

Follicle Recruitment

At the start of each cycle, FSH rescues 15-20 primary (preantral) follicles from a continuously forming pool of primordial follicles. Without FSH, these primary follicles undergo atresia. No new ova are formed after birth - at birth, 1-2 million oocytes are present; by puberty ~400,000 remain; over a lifetime only ~400 are ever ovulated.

Follicle Development: The "Two-Cell, Two-Gonadotropin" Model

Theca interna cells (LH-stimulated): synthesize androgens (androstenedione, testosterone)
Granulosa cells (FSH-stimulated): express aromatase, converting androgens to estrone and 17β-estradiol
Theca cells lack aromatase, so androgens must diffuse into granulosa cells to be converted. FSH stimulates aromatase activity.

Proliferation of granulosa cells is also mediated by growth differentiation factor-9 (GDF-9), a TGF-β family member.

Dominant Follicle Selection

By ~day 6, one follicle becomes the dominant (Graafian) follicle - selected by its superior ability to produce intrafollicular estrogen needed for final maturation. The others undergo apoptotic atresia, forming corpora atretica. When exogenous gonadotropins are given, multiple follicles mature simultaneously, explaining the risk of multiple pregnancies with fertility drugs.

The dominant follicle grows to a mature vesicular (Graafian) follicle (~25 mm diameter) with a fluid-filled antrum by the end of the follicular phase.

Estrogen effects during follicular phase:

Stimulates endometrial proliferation (proliferative phase)
Thins cervical mucus (sperm passage)
Positively feeds back on anterior pituitary to trigger the LH surge

Oogenesis and follicle development - from primordial germ cell to corpus luteum

Ovulation (Day ~14)

The rising estradiol from the dominant follicle triggers a positive feedback on the pituitary, causing an abrupt LH surge (and a smaller FSH surge). This surge causes:

The primary oocyte to complete Meiosis I → secondary oocyte + first polar body
Meiosis II is initiated, but arrested at metaphase II (~3 hours before ovulation)
Luteinization of follicular stromal cells begins (progesterone production starts)
Increased collagenase activity digests collagen surrounding the follicle
Prostaglandin levels rise, causing muscular contractions in the ovarian wall
An avascular spot (stigma) forms at the apex of the bulging follicle
The follicle ruptures - the oocyte with surrounding cumulus oophorus cells floats free
Cumulus cells rearrange to form the corona radiata around the zona pellucida

The oocyte is picked up by the fimbriated ends of the uterine tube and transported toward the uterus. Meiosis II is completed only at fertilization (with release of the second polar body). If unfertilized, the oocyte degenerates.

Mittelschmerz: Minor peritoneal irritation from follicular fluid/blood may cause brief mid-cycle lower abdominal pain.

Phase 2: Luteal Phase (Days 15-28)

Corpus Luteum Formation

After ovulation, the ruptured follicle fills with blood (corpus hemorrhagicum). Under the continued influence of LH:

Granulosa cells + theca interna cells proliferate and become vascularized (VEGF is essential for developing the blood supply)
Cells accumulate yellowish lipid and lutein pigment, differentiating into lutein cells
This structure = the corpus luteum, which secretes both progesterone (dominant) and estrogen

Actions of Corpus Luteum Hormones

Progesterone: converts endometrium to secretory/progestational phase, preparing for implantation; also promotes breast lobular-alveolar development
Estrogen + progesterone: together maintain the secretory endometrium
Inhibin (also secreted): suppresses FSH from the anterior pituitary

Fate of the Corpus Luteum

If no fertilization: Corpus luteum begins to degenerate ~Day 24 (4 days before next menses). By Day 26-28, involution is complete. The structure is replaced by fibrotic scar tissue = corpus albicans
If pregnancy occurs: The trophoblast secretes hCG (human chorionic gonadotropin), which has LH-like activity and rescues the corpus luteum - it persists and continues secreting progesterone to maintain the pregnancy until the placenta takes over (~weeks 8-10)

Start of New Cycle

The sharp fall in estrogen, progesterone, and inhibin removes negative feedback on the pituitary. FSH and LH rise again, initiating recruitment of the next cohort of follicles. Simultaneously, the lack of progesterone/estrogen triggers menstruation.

Summary Table

Event	Day	Trigger
FSH/LH begin to rise	1	Fall in P4/E2/inhibin from previous corpus luteum
Follicle recruitment (15-20)	1-5	FSH
Dominant follicle selected	~6	Local estrogen environment
Estradiol peaks	~12-13	Growing Graafian follicle
LH surge	~13-14	Estradiol positive feedback
Ovulation	~14	LH surge
Corpus luteum forms	14-15	LH (luteinization)
Progesterone peaks	~21	Corpus luteum activity
Corpus luteum degenerates	~24-26	No hCG stimulus
Menstruation	28/1	Withdrawal of P4 + E2

Clinically Relevant Points

Point	Detail
Anovulation	Low GnRH/FSH/LH - treated with clomiphene or gonadotropins (risk: multiple ovulation)
Fertile window	5 days before + day of ovulation (sperm survive ~5 days)
Basal temperature	Rises ~0.5°C after ovulation (progesterone thermogenic effect)
Premature ovarian insufficiency	Loss of follicle pool before age 40
Polycystic ovary syndrome (PCOS)	LH:FSH imbalance, excess androgens, anovulation, multiple arrested antral follicles
Luteal phase defect	Inadequate progesterone from corpus luteum - implantation failure

Sources:

Guyton and Hall Textbook of Medical Physiology, Chapters 82-83 (Ovarian Cycle, Gonadotropins, Ovarian Hormones)
Ganong's Review of Medical Physiology, 26th Ed., Chapter 22 (Ovarian Cycle, Estrogen/Progesterone)
Langman's Medical Embryology, Chapter 3 (Ovarian Cycle, Ovulation, Corpus Luteum)

Menstrual cycle

Finding Sources

Searching Images

menstrual cycle endometrial changes proliferative secretory menstruation phases diagram

This composite educational graphic illustrates the morphological and hormonal changes of the human endometrium across a standard 28-day uterine cycle. The top section features a pathophysiology diagram showing fluctuations in estradiol (E2) and progesterone (P). E2 peaks during the proliferative phase, correlating with endometrial growth, while P dominates the secretory phase, driving glandular coiling and the 'window of implantation' (WOI). Below the hormone curves, a cross-sectional illustration depicts the histological evolution of endometrial glands and spiral arteries. It transitions from a thin, shedding layer in the menstrual phase to elongated glands during the proliferative phase, and finally to highly coiled, secretory glands with increased angiogenesis in the secretory phase. The bottom section displays three diagnostic ultrasound images of the uterus, providing clinical correlation of endometrial thickness: 2 mm (early proliferative), 11 mm (late proliferative), and 14 mm (mid-secretory). Key physiological processes such as post-menstrual repair, cellular proliferation, angiogenesis, and stromal decidualization are annotated to link hormonal signaling with macroscopic and microscopic changes.

This composite educational resource compares 2D and 3D transvaginal color Doppler sonography (TV-CDS) for evaluating pelvic vascularity. (a) A cross-sectional anatomical diagram and 2D TV-CDS image highlight the uterine vascular hierarchy during the follicular phase, depicting arcuate, radial, and spiral vessels. (b) A timeline diagram illustrates endometrial vascular changes across the menstrual cycle phases: Menstrual, Proliferative, Secretory, and Ischemic. This is paired with a 2D TV-CDS showing the characteristic increase in spiral vessel density during the luteal phase. (c) The bottom section focuses on the corpus luteum, featuring a diagram of the female reproductive system with a magnified view of ovarian vascularization. Below this, multiplanar 3D TV-CDS images (longitudinal, axial, and coronal planes) and a high-definition 3D reconstruction demonstrate the pathognomonic vascular 'wreath'—a dense circumferential ring of blood vessels surrounding the functioning corpus luteum. This content illustrates key gynecological sonography concepts, including the cyclical nature of endometrial perfusion and the advanced spatial assessment afforded by 3D Doppler imaging for ovarian structures.

A side-by-side comparison of two macroscopic cross-sections of a rhesus macaque uterus, demonstrating physiological changes during the menstrual cycle. Image (a) represents the proliferative phase (day 14), showing a thickened endometrium (Endo) with a pale tan-to-pink hue. A clear blue line highlights the smooth, well-defined endometrial-myometrial border, with the underlying myometrium (Myo) clearly visible. Image (b) represents the second day of the menstrual phase, where the endometrium appears significantly thinner due to tissue sloughing and breakdown. In this phase, the upper third of the endometrium (functionalis zone) is visibly engorged with blood, exhibiting a deep red, hemorrhagic appearance, while the basalis layer remains intact. The endometrial-myometrial junction in the menstruating specimen is less distinct compared to the proliferative phase. A 1 cm scale bar is provided for reference. This comparison illustrates the cyclic changes in endometrial thickness, vascularity, and tissue integrity characteristic of menstruating primates.

Reading File

Loading Image

Reading File

Loading Image

I now have thorough content from Berek & Novak's Gynecology, Tietz Laboratory Medicine, Costanzo Physiology, and Junqueira's Histology. I have enough for a comprehensive answer.

The Menstrual Cycle

The menstrual cycle is the monthly, hormonally-driven sequence of coordinated changes in the hypothalamus, pituitary, ovary, and uterus (endometrium) that prepares the female reproductive tract for pregnancy. It averages 28 days (normal range: 21-35 days) and is counted from the first day of menstrual bleeding.

The cycle has two parallel components:

Ovarian cycle: Follicular phase → Ovulation → Luteal phase
Uterine (endometrial) cycle: Menstrual phase → Proliferative phase → Secretory phase → (Premenstrual phase)

Menstrual cycle - endocrine, ovarian, endometrial histology, and basal body temperature across 28 days

The Hormonal Framework

The entire cycle is regulated by a neuroendocrine axis:

Hypothalamus → GnRH (pulsatile) → Anterior pituitary → FSH + LH → Ovary → E₂ + Progesterone → Feedback

There are two feedback centers in the hypothalamus:

Tonic negative feedback center (basal medial hypothalamus): activated by low E₂ and by progesterone + E₂ in the luteal phase
Cyclic positive feedback center (anterior hypothalamus): triggered by the high pre-ovulatory E₂ surge, producing the LH surge

GnRH is pulsatile - the pulse frequency determines the ratio of LH:FSH secreted. GnRH also has a self-priming effect (each dose potentiates subsequent doses).

Phase 1: Menstrual Phase (Days 1-5)

Trigger: Fall in estrogen and progesterone as the corpus luteum degenerates (in the absence of hCG from a pregnancy)

Mechanism:

Progesterone withdrawal causes spiral artery vasoconstriction → ischemia of the endometrial functional layer
Intermittent constriction and relaxation interrupts blood flow
Local prostaglandin release amplifies vasoconstriction
Hypoxic cells release cytokines → immigration of leukocytes → release of collagenase and matrix metalloproteinases (MMPs) → degrade basement membranes and ECM
The functional layer (stratum functionalis) of the endometrium detaches and sloughs with blood from open venule ends = menstrual flow
The basal layer (stratum basalis) is spared - it is supplied by straight (not spiral) arteries and is not progesterone-dependent; it serves as the regenerative reserve

Normal parameters:

Duration: 2-6 days (average 4-5 days)
Blood loss: 20-60 mL (average 30 mL)
Discharge: degenerating endometrium + blood + prostaglandins

At the end of the menstrual phase, the endometrium is reduced to a thin layer (~0.5 mm), ready to regenerate.

Phase 2: Proliferative Phase (Days 6-13) - "Follicular phase" of the uterus

Trigger: Rising FSH stimulates follicular growth → rising estradiol (E₂)

Mechanism - driven entirely by estrogen:

Epithelial cells from the broken gland bases proliferate, migrate, and re-cover the denuded surface
Endometrial glands: short, straight tubules, narrow lumens, mitotically active
Stroma: regenerates with mitotic activity in fibroblasts
Spiral arteries lengthen; extensive microvasculature begins forming near the surface
By end of phase: endometrium is 2-3 mm thick, glands elongated

Cervical mucus changes (estrogen effect):

Becomes copious, watery, elastic (spinnbarkheit)
On a glass slide: shows ferning pattern (arborization)
Physical channels form allowing sperm penetration - maximally fertile

Simultaneously in the ovary: One dominant follicle grows to ~25 mm, secreting increasing E₂. Rising E₂ feeds back positively on the pituitary.

Hormonal dynamics:

FSH rises briefly at start (from corpus luteum demise of previous cycle), then falls as E₂ and inhibin B suppress it
E₂ rises steadily; pre-ovulatory peak: 250-500 pg/mL
LH is initially suppressed by negative feedback from E₂, then switches to positive feedback as E₂ peaks → LH surge

Ovulation (~Day 14)

The midcycle LH surge (onset 16-58 hours before ovulation; peak 3-36 hours before) causes:

Completion of Meiosis I in the oocyte → secondary oocyte
Follicle rupture and oocyte release
Luteinization of granulosa/theca cells begins

Note: Cycle length variability is almost entirely due to variation in the follicular phase length. The luteal phase is remarkably constant at ~14 days.

Uterine cycle with endometrial, hormonal (E₂ and P), and ultrasound correlation

Phase 3: Secretory Phase (Days 15-28) - "Luteal phase" of the uterus

Trigger: Progesterone (+ estrogen) from the corpus luteum

Mechanism:

Proliferation of endometrium slows; overall thickness may decrease slightly then build
Glands: become tortuous, coiled, wide-lumened; epithelial cells accumulate glycogen in subnuclear vacuoles (earliest histological sign, day 16-17), then secrete glycogen into lumen
Stroma: becomes edematous; stromal cells begin decidualization (enlargement, accumulation of glycogen and lipid)
Spiral arteries: elongate further and become tightly coiled
Superficial microvasculature: develops thin-walled, blood-filled lacunae
At peak (mid-secretory): endometrium reaches maximum thickness of 5-6 mm
The "window of implantation" (WOI) is approximately LH+6 to LH+10 days - when endometrial receptivity is optimal

Cervical mucus changes (progesterone effect):

Becomes thick, viscous, non-elastic
Does not fern on a glass slide
Impenetrable to sperm (the "fertile window" has closed)

Basal body temperature (BBT):

Rises ~0.5°C after ovulation due to the thermogenic effect of progesterone
Remains elevated throughout the luteal phase
Used retrospectively to confirm ovulation (the "rhythm method")

Hormonal dynamics:

Progesterone peaks ~8 days after ovulation (~Day 22); levels >3 ng/mL confirm ovulation
E₂ dips briefly post-ovulation then rises again from corpus luteum → reaches ~125 pg/mL
Inhibin A secreted by corpus luteum
High P + E₂ → negative feedback → suppresses FSH and LH

Phase 4: Premenstrual Phase (Days 26-28)

Trigger: Corpus luteum involution → sharp fall in P + E₂ + Inhibin

Mechanism:

Spiral arteries constrict intermittently → focal hypoxia
Glands begin to swell then dissolve
Stroma compacts peripherally; becomes spongy near the basalis
Apoptosis, blood stasis, and proteolytic matrix breakdown set the stage for menstruation
Fall in Inhibin A and E₂ removes negative feedback → FSH begins to rise → new cohort of follicles is recruited for the next cycle

Complete Hormonal Timeline

Day	FSH	LH	E₂	Progesterone	Endometrium
1-5	Rising	Low	Low/falling	Low/falling	Menstruation
5-13	Falling	Low then rising	Rising	Low	Proliferative
12-13	Small surge	LH surge	Peak (~350 pg/mL)	Begins rising	Late proliferative
14	-	Post-surge	Falling	Low	Ovulation
15-21	Suppressed	Low	Mid-luteal rise	Rising	Early secretory
21-23	Suppressed	Low	~125 pg/mL	Peak ~8-12 ng/mL	Mid-secretory (WOI)
24-28	Rising again	Low	Falling	Falling	Premenstrual → menses

Endometrial Layers and Their Fate

Layer	Arterial supply	Hormone-dependent	Fate in menstruation
Stratum functionalis (2/3 outer)	Spiral arteries	Yes (progesterone-sensitive)	Shed with each cycle
Stratum basalis (inner 1/3)	Straight (basal) arteries	No	Retained; regenerates the functional layer

Changes Beyond the Uterus

Target	Estrogen effects	Progesterone effects
Cervix	Thin, watery, fern-like mucus; open os	Thick, hostile mucus; closed
Vagina	Epithelial proliferation; superficial cells predominate	Intermediate cells predominate; drier
Breasts	Ductal growth; lobular development	Secretory activity in ducts; tenderness
Temperature	No significant effect	BBT rise of ~0.5°C
Myometrium	Increased contractility	Inhibits contractions (preserves potential implantation)

Clinical Correlates

Condition	Mechanism
Dysmenorrhea	Excess prostaglandins (PGF₂α, PGE₂) during menstruation → myometrial spasm
Amenorrhea	Primary (no menarche) or secondary (cessation); causes span hypothalamic-pituitary-ovarian axis
Oligomenorrhea	Cycles >35 days; often anovulatory
Anovulatory cycles	No LH surge → no corpus luteum → no progesterone → unopposed estrogen → endometrial hyperplasia risk
Endometriosis	Viable endometrial cells reflux through tubes → implant in pelvis; under cyclic hormonal control
Premenstrual syndrome (PMS/PMDD)	Sensitivity to normal luteal hormonal fluctuations
Luteal phase defect	Inadequate P secretion → poor secretory transformation → implantation failure
Abnormal uterine bleeding (AUB)	Classified by PALM-COEIN (structural vs. non-structural causes)

Sources:

Berek & Novak's Gynecology - Chapter 7 (Menstrual Cycle Physiology, Hormonal Variations, Normal Menstrual Cycle)
Tietz Textbook of Laboratory Medicine, 7th Ed. - Chapter 58 (Normal Menstrual Cycle, Hormonal Dynamics)
Costanzo Physiology, 7th Ed. - Chapter on Reproductive Physiology (Proliferative and Secretory Phases)
Junqueira's Basic Histology, 17th Ed. - Chapter 22 (Endometrial Histology Across the Menstrual Cycle)

-physiological changes in pregnancy -parturition or Ferguson reflex •⁠ ⁠physiology of lactation •⁠ ⁠benefits of breast feeding to mother and child •⁠ ⁠estrogen ( MOA, functions, applied aspect) •⁠ ⁠testosterone (MOA, findings and applied aspect) •⁠ ⁠infertility ( causes in men women, investigations, diagnostic procedures, and treatment )

Finding Sources

Reading File

Searching Images

pregnancy physiological changes cardiovascular respiratory uterus adaptation

$This cardiovascular magnetic resonance (CMR) comparison illustrates left ventricular (LV) remodeling and tissue characterization in a representative pregnant woman across three stages: 2nd trimester, 3rd trimester, and 1 month postpartum. The top rows feature structural cine images in short-axis (SAX) and four-chamber (4ch) views, demonstrating longitudinal changes in end-diastolic volume, ejection fraction, and LV mass. The bottom row presents native T1 mapping using the MOLLI (Modified Look-Locker Inversion recovery) sequence at 1.5 Tesla. These color-coded parametric maps represent myocardial T1 values, with a provided scale ranging from 0 to 2000 ms. Quantitatively, the native T1 values fluctuate from 1,206 ms in the 2nd trimester, decreasing to 1,025 ms in the 3rd trimester, and recovering to 1,128 ms postpartum. Visually, this is reflected in the shift from higher T1 areas (pink/yellow) to lower T1 regions (green/blue) and back. This visual comparison is educationally significant for understanding physiological cardiac adaptation during pregnancy and the role of non-contrast CMR in assessing myocardial tissue properties and peripartum cardiomyopathy (PPCM).$

This cardiovascular magnetic resonance (CMR) comparison illustrates left ventricular (LV) remodeling and tissue characterization in a representative pregnant woman across three stages: 2nd trimester, 3rd trimester, and 1 month postpartum. The top rows feature structural cine images in short-axis (SAX) and four-chamber (4ch) views, demonstrating longitudinal changes in end-diastolic volume, ejection fraction, and LV mass. The bottom row presents native T1 mapping using the MOLLI (Modified Look-Locker Inversion recovery) sequence at 1.5 Tesla. These color-coded parametric maps represent myocardial T1 values, with a provided scale ranging from 0 to 2000 ms. Quantitatively, the native T1 values fluctuate from 1,206 ms in the 2nd trimester, decreasing to 1,025 ms in the 3rd trimester, and recovering to 1,128 ms postpartum. Visually, this is reflected in the shift from higher T1 areas (pink/yellow) to lower T1 regions (green/blue) and back. This visual comparison is educationally significant for understanding physiological cardiac adaptation during pregnancy and the role of non-contrast CMR in assessing myocardial tissue properties and peripartum cardiomyopathy (PPCM).

This diagnostic image displays a series of Cine Cardiovascular Magnetic Resonance (CMR) scans from a representative pregnant woman, organized to compare cardiac structure across three time points: 2nd trimester, 3rd trimester, and one month postpartum. The top row presents the short-axis (SAX) view at the mid-ventricular level, while the bottom row shows the horizontal long-axis (4-chamber) view. The images illustrate physiological cardiac remodeling during pregnancy. Key observations include a visible increase in left ventricular (LV) mass and end-diastolic volume during the 3rd trimester compared to the postpartum baseline. In the SAX view, the LV myocardium appears slightly thicker in the 3rd trimester, while the 4-chamber view demonstrates the maintenance of normal ventricular geometry and relationship between the LV and right ventricle (RV). These images serve as educational materials for understanding the reversible eccentric hypertrophy and volume expansion that characterize healthy maternal cardiovascular adaptation to pregnancy.

Searching Images

lactation breast milk let-down reflex prolactin oxytocin diagram

A pathophysiology diagram illustrating the brain-breast-bone axis and its regulation of mineral metabolism during lactation. The diagram begins with the 'suckling' stimulus, which triggers neural pathways to the brain and mammary gland. In the 'brain' section, suckling leads to increased levels of oxytocin and prolactin. Elevated prolactin inhibits Gonadotropic Releasing Hormone (GnRH), subsequently decreasing Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH), which leads to reduced estradiol levels in the bloodstream. In the 'breast' section, suckling and prolactin increase Parathyroid Hormone-related Protein (PTHrP) and serotonin levels. The Calcium Sensing Receptor (CaSR) is shown providing negative feedback on PTHrP when mammary calcium levels are high. In the 'bone' section, the combined effect of low estradiol and high PTHrP increases the RANKL/OPG ratio, leading to stimulated bone resorption and bone formation (osteoclastic and osteocytic activity). This process liberates calcium into the circulation to be utilized by the mammary gland for milk production. The diagram effectively maps the hormonal cascade coordinating maternal skeletal turnover with neonatal nutritional demands.

This clinical photograph displays a right lactating breast during the milk ejection reflex, alongside the application of a diagnostic ultrasound probe. The areola demonstrates significant physiological swelling and increased tension, resulting in a full, convex appearance. This visual change is indicative of the expansion of superficial milk ducts as oxytocin-induced myoepithelial contraction forces milk from the alveoli into the ductal system. A linear ultrasound transducer is positioned in direct contact with the inferior portion of the areola, stabilized by a hand to monitor ductal dilation and milk flow in real-time. The skin surface shows slight lobulation or prominence corresponding to the underlying distended ducts. This image illustrates the physical manifestations of the milk ejection reflex and the non-invasive clinical method of using ultrasound to study lactation physiology and breastfeeding dynamics.

Reading File

Searching Images

infertility male female causes semen analysis IVF treatment

Summary : This figure presents the recommended initial clinical assessment steps for infertility in females and males, listing specific diagnostic procedures for each sex. flowchart: # Female Assessment : • Medical history • Physical examination • Pelvic 2D ultrasound for detection of structural abnormalities, with additional imaging if needed • Assessment of ovulatory function via menstrual calendar and laboratory testing • AMH (Anti-Müllerian Hormone) or other ovarian reserve testing # Male Assessment : • Medical history • Physical examination • Semen analysis # Symbols : • Female symbol (♀) for female assessment section • Male symbol (♂) for male assessment section Analysis : • The figure clearly separates the infertility assessment protocols for females and males, with more detailed and varied diagnostic steps for females, including imaging and hormonal testing, while the male assessment focuses on semen analysis after history and examination. This highlights the complexity and multi-factorial nature of female infertility evaluation compared to male.

11.3.7 Summary of evidence and recommendations for the diagnostic work-up of male infertility <table><thead><tr><th>Summary of evidence</th><th>LE</th></tr></thead><tbody><tr><td>Semen analysis alone cannot distinguish fertile from infertile men.</td><td>2a</td></tr><tr><td>Diagnosis of male infertility is associated with an increased risk of malignant and non-malignant comorbidities.</td><td>2a</td></tr><tr><td>Male infertility evaluation should include a medical, reproductive and family history, assessment of lifestyle and behavioural risk factors, physical examination, semen analysis and hormonal evaluation.</td><td>2a</td></tr><tr><td>Genetic analysis and imaging may be required depending on the clinical features and semen parameters.</td><td>2a</td></tr><tr><td>Testicular volume can be measured with a Prader's orchidometer or using testicular ultrasound.</td><td>2a</td></tr></tbody></table>

Searching Images

estrogen receptor mechanism of action nuclear signaling

This pathophysiology diagram illustrates the dual mechanisms of estrogenic action: the classical and non-classical estrogen receptor (ER) pathways. The diagram is divided into extracellular space, cytoplasm, and nucleus. On the left, the 'Classical ER Pathway' depicts estrogen molecules entering the cell and binding to intracellular ERα and ERβ receptors. This ligand-receptor complex, alongside transcription factors c-fos and c-jun, translocates into the nucleus to bind with the Estrogen Response Element (ERE) in the gene promoter region, directly initiating transcription. On the right, the 'Non-Classical ER Pathway' shows estrogen binding to membrane-bound receptors (ERα, ERβ, or GPCR30). This interaction triggers rapid non-genomic signaling through calcium (Ca2+) mobilization and protein kinase cascades, specifically the Raf/MEK/ERK and MAPK/PI3K/AKT/PKA pathways. These cascades lead to the phosphorylation of transcription factors (TF) and secondary modulation of gene expression, facilitating outcomes such as cell survival, synaptogenesis, and enhanced metabolism. This diagram serves as a high-level educational resource for endocrinology and cellular biology, highlighting genomic versus rapid non-genomic signaling.

This pathophysiology diagram illustrates the suggestive molecular mechanism of action for the FADS2 gene variant rs174575 (CC homozygote) in relation to metabolic health. The diagram shows a DNA strand containing the FADS2 gene, which promotes increased Polyunsaturated Fatty Acid (PUFA) metabolism. This metabolic process yields biological ligands including PUFAs, leukotrienes, and prostaglandins. These biological ligands, along with other exogenous ligands, bind to and activate the Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ). The activated PPAR-γ forms a heterodimer with the Retinoid X Receptor (RXR), which then binds to the Peroxisome Proliferator Response Element (PPRE) on the DNA. This nuclear signaling pathway leads to specific physiological outcomes: increased insulin sensitivity, enhanced glucose uptake, and lipid lowering. The visual uses standard biochemical notation to represent the transcriptional regulation involved in lipid and glucose homeostasis, emphasizing the protective role of the wild-type FADS2 genotype against insulin resistance.

Reading File

Loading Image

Reading File

Loading Image

Finding Sources

Here is a complete, system-by-system guide to all six topics:

1. Physiological Changes in Pregnancy

Pregnancy produces adaptive changes in virtually every organ system to meet the increased metabolic demands of the mother and growing fetus.

Cardiovascular Changes

Parameter	Change	Magnitude
Blood volume	Increases	+35%
Plasma volume	Increases (dilutional "anaemia of pregnancy")	+55%
Cardiac output	Increases	+40%
Stroke volume	Increases	+30%
Heart rate	Increases	+20%
Systolic BP	Slightly decreases	-5%
Diastolic BP	Decreases (peripheral vasodilation)	-15%
Peripheral resistance	Decreases	-15%
Pulmonary vascular resistance	Decreases	-30%

The disproportionate rise in plasma volume (55%) over red cell mass causes a fall in haematocrit - physiological anaemia of pregnancy
CO rises further during uterine contractions in labor
Supine hypotension syndrome: the gravid uterus compresses the inferior vena cava when lying supine → decreased venous return → hypotension (relieved by left lateral decubitus)

Respiratory Changes

Parameter	Change
O₂ consumption	+20-50%
Minute ventilation	+50%
Tidal volume	+40%
Respiratory rate	+15%
FRC (functional residual capacity)	-20% (elevated diaphragm)
PaO₂	+10%
PaCO₂	-15% (compensated respiratory alkalosis)
HCO₃⁻	-15% (renal compensation)
Airway resistance	-35% (progesterone relaxes bronchial smooth muscle)

Dyspnoea of pregnancy is common (normal) due to elevated progesterone stimulating the respiratory centre
Reduced FRC means decreased oxygen reserve - rapid desaturation with apnoea

Renal Changes

GFR increases by +50% (due to increased renal plasma flow)
Creatinine and urea levels fall (lower-than-normal = "normal in pregnancy")
Glycosuria may occur even with normal blood glucose (GFR exceeds tubular reabsorption capacity)
Hydronephrosis of pregnancy: progesterone relaxes ureteric smooth muscle + uterine compression

Haematological Changes

Haemoglobin falls ~20% (dilutional)
Platelets fall slightly (~10%)
Clotting factors rise +30-250% (hypercoagulable state - protects against haemorrhage at delivery but raises DVT/PE risk)
WBC rises (leukocytosis, up to 15,000/μL)

Neurological Changes

MAC (minimum alveolar concentration) for all inhalational anaesthetics decreases by up to 40% at term (progesterone is sedating; β-endorphin surge in labor also contributes)
Enhanced sensitivity to local anaesthetics

Gastrointestinal Changes

Progesterone relaxes lower oesophageal sphincter → GERD and heartburn
Gastric emptying delayed → increased aspiration risk in anaesthesia
Constipation (progesterone slows peristalsis; iron supplementation)
Liver: alkaline phosphatase rises (placental origin), albumin falls

Endocrine/Metabolic Changes

Insulin resistance increases in later pregnancy (hPL - human placental lactogen is the major culprit) → gestational diabetes risk
Thyroid: TBG increases → total T3/T4 rise but free levels normal; hCG has weak TSH-like activity (first trimester)
Relaxin (from corpus luteum and placenta): relaxes pelvic ligaments, softens cervix

Uterine Changes

Uterus grows from ~50g to ~1 kg by term
Progesterone maintains uterine quiescence (inhibits contractions, reduces gap junctions)
Braxton Hicks contractions (irregular, painless) begin ~1 month before term

2. Parturition and the Ferguson Reflex

Mechanism of Parturition

There is still considerable uncertainty about the precise trigger for labor, but the following hormonal events converge:

The Fetal Contribution ("The fetus picks the time to be born")

The fetal hypothalamic-pituitary-adrenal axis activates near term
Fetal adrenal cortex secretes large amounts of cortisol
Fetal hypothalamus also increases CRH secretion, supplemented by increased placental CRH
This raises fetal ACTH → more cortisol → hastens maturation of the fetal lung (surfactant production)

The Estrogen/Progesterone Shift

Fetal cortisol increases the estrogen:progesterone ratio in the mother
Estrogen increases uterine excitability, increases gap junctions between myometrial cells, stimulates prostaglandin production, and up-regulates oxytocin receptors
Progesterone previously maintained quiescence by inhibiting oxytocin action and reducing gap junctions - its relative fall removes this brake

Role of Prostaglandins (PGE₂ and PGF₂α)

Estrogen-stimulated, progesterone-inhibited. At term, the rise in E:P ratio promotes local prostaglandin production which:

Increases intracellular Ca²⁺ in uterine smooth muscle → increases contractility
Promotes gap junction formation between myometrial cells → coordinated, synchronous contractions
Causes cervical ripening: softening, effacement (thinning), and early dilation

Role of Oxytocin

Oxytocin receptors in the myometrium increase >100-fold during pregnancy, peaking at early labor (estrogen up-regulates receptors)
Maternal blood oxytocin levels paradoxically do not rise significantly near term
The marked receptor up-regulation enables the uterus to respond to normal plasma oxytocin concentrations
Locally produced oxytocin (uterine mRNA increases at term) also participates
Oxytocin acts by: (1) directly contracting uterine smooth muscle cells and (2) stimulating prostaglandin formation in the decidua, which enhances contractions

The Ferguson Reflex (Positive Feedback Loop)

This is the positive-feedback neuroendocrine reflex that amplifies and sustains labor once started:

Uterine contractions → Cervical dilation and vaginal distension → Afferent neural signals to hypothalamus/posterior pituitary → Increased oxytocin secretion → More uterine contractions → More cervical dilation → More oxytocin...

Ferguson reflex - role of oxytocin in parturition: positive feedback loop

This positive feedback loop terminates only on delivery of the fetus and placenta. It explains why, once active labor begins, it becomes self-sustaining.

Clinical application: Exogenous oxytocin (Syntocinon/Pitocin) is used to induce or augment labor. Progesterone (17α-hydroxyprogesterone) is used to prevent premature labor by opposing these mechanisms.

Three Stages of Labor

First stage: Contractions from fundus sweeping downward move the fetal head toward the cervix; progressive cervical effacement and dilation (0→10 cm)
Second stage: Fetus forced through the cervix and delivered vaginally (voluntary "bearing down" also helps)
Third stage: Placenta separates and is delivered; powerful uterine contractions constrict uterine blood vessels → limits postpartum haemorrhage

3. Physiology of Lactation

Breast Development During Pregnancy

Estrogens stimulate proliferation of the ductile system and stromal tissues
Progesterone develops the lobulo-alveolar system
Prolactin levels rise steadily throughout pregnancy (stimulated by estrogen)
Despite high prolactin levels, lactation does NOT occur during pregnancy because estrogen and progesterone block prolactin's action on the breast ("lactation inhibition")

Initiation of Lactation Post-Delivery

At delivery, estrogen and progesterone levels fall precipitously → their inhibitory block on the breast is removed
Prolactin levels remain high (especially if breastfeeding)
Lactation can now proceed
The first secretion is colostrum - protein-rich, high in immunoglobulins (IgA), low in fat and lactose; important for passive immunity

Colostrum vs. Mature Milk (per 100g):

Component	Colostrum	Mature Human Milk	Cow's Milk
Protein	2.7g (high)	1.2g	3.3g
Lactose	5.3g	6.8g	5.0g
Fat	2.9g	3.8g	3.7g
Casein:whey	-	1:2	3:1
IgA	Very high	Present	Very low

Maintenance of Lactation: The Suckling Reflex

Suckling → Two parallel neuroendocrine reflexes:

A. Prolactin reflex (milk production):

Suckling stimulates nipple mechanoreceptors → afferent neural signals to hypothalamus → inhibits dopamine (prolactin-inhibiting factor) release → anterior pituitary releases prolactin
Prolactin acts on alveolar epithelial cells (lactocytes) to stimulate milk synthesis (casein, lactalbumin, lactose, lipids)

B. Milk ejection (let-down) reflex:

Suckling + nipple stimulation → hypothalamus → posterior pituitary releases oxytocin
Oxytocin causes contraction of myoepithelial cells surrounding alveoli → milk ejected into ducts → delivered through nipple
Conditioned reflex: even the sound of a baby crying can trigger oxytocin release and milk let-down

Suckling-prolactin-oxytocin-bone axis during lactation

Lactation-Induced Amenorrhoea

High prolactin inhibits GnRH secretion from the hypothalamus
This suppresses FSH and LH → anovulation and amenorrhoea during lactation
Acts as natural (but not 100% reliable) contraception

4. Benefits of Breastfeeding

Benefits to the Child

Benefit	Mechanism
Passive immunity	sIgA, lactoferrin, lysozyme, macrophages in milk protect against gut/respiratory infections
Optimal nutrition	Correct protein:fat:carbohydrate ratio, DHA for brain development
Reduced SIDS risk	Protective mechanism unclear but well-documented
Reduced allergy/asthma	Early immune modulation
Reduced obesity/type 2 DM risk	Leptin in milk; metabolic programming
Reduced necrotising enterocolitis	Especially in premature infants
Better cognitive development	DHA, arachidonic acid for neural myelination
Dental benefits	Jaw development with suckling

Benefits to the Mother

Benefit	Mechanism
Uterine involution	Oxytocin released with suckling contracts the uterus back to pre-pregnancy size; reduces postpartum haemorrhage
Lactational amenorrhoea	Natural contraception/child spacing
Reduced breast cancer risk	Long-term, cumulative; related to suppression of ovulation and direct mammary effects
Reduced ovarian cancer risk	Hormonal suppression
Reduced type 2 DM risk	Enhanced glucose metabolism during lactation
Bone: net neutral/positive	Although calcium is mobilised during lactation, bone density recovers fully after weaning
Weight loss	~500 kcal/day expended in milk production
Psychological bonding	Oxytocin promotes maternal-infant attachment

5. Estrogen - MOA, Functions, and Applied Aspects

Synthesis

Source: granulosa cells of ovarian follicles (primary), corpus luteum, placenta, adrenal cortex (minor), adipose tissue (peripheral aromatization)
Substrate: cholesterol → androgens (from theca cells) → aromatized to estrogens by granulosa cells
Three major estrogens (in order of potency): 17β-estradiol (E₂) > estrone (E₁) > estriol (E₃)
β-Estradiol is 12× more potent than estrone and 80× more potent than estriol
Transport: bound to plasma albumin and sex hormone-binding globulin (SHBG)
Metabolism: liver conjugates to glucuronides and sulfates → excreted in urine and bile; liver converts E₂/E₁ → estriol (inactive)

Mechanism of Action (MOA)

Estrogen uses both genomic (classical) and non-genomic (non-classical) pathways:

Estrogen receptor classical vs non-classical signaling pathways

Classical / Genomic Pathway:

Estrogen (lipid-soluble) diffuses across cell membrane
Binds intracellular ERα and ERβ receptors (nuclear receptor superfamily)
Estrogen-ER complex dimerizes, translocates to nucleus
Binds to Estrogen Response Elements (EREs) in the promoter regions of target genes (with co-activators c-fos, c-jun)
Activates gene transcription → new mRNA → protein synthesis
Effects take hours to days (slow, sustained)

Non-Classical / Non-Genomic Pathway:

Estrogen binds to membrane-bound receptors (ERα, ERβ, or GPCR30/GPR30)
Rapid intracellular signalling cascades: Ca²⁺ mobilization, Raf/MEK/ERK, MAPK, PI3K/AKT/PKA
Phosphorylation of transcription factors (indirect gene effects)
Effects occur in seconds to minutes (rapid, non-genomic)
Mediates cell survival, proliferation, synaptic plasticity, enhanced glycolytic metabolism

Functions of Estrogen

On Reproductive Tract:

Uterus: proliferation of endometrium; increased size 2-3× at puberty
Vagina: cuboidal → stratified epithelium (more resistant to infection)
Fallopian tubes: proliferation of glandular epithelium; increases ciliary number and beat frequency (propels ovum toward uterus)
Cervix: thin, watery, fern-patterned mucus; sperm penetration facilitated

On Breasts:

Stromal growth, ductal proliferation, fat deposition
External shape of mature breast
(Progesterone + Prolactin complete lobulo-alveolar development and milk production)

On Skeleton:

Inhibits osteoclastic activity (stimulates osteoprotegerin/OPG)
Promotes bone growth at puberty
Causes epiphyseal fusion (earlier than in males → females stop growing earlier)
Protects against osteoporosis during reproductive years

Systemic Effects:

Slightly increases protein deposition (much less than testosterone)
Increases body fat in breasts, buttocks, thighs (female fat distribution)
Increases whole-body metabolic rate (~1/3 that of testosterone)
Na⁺ and water retention (aldosterone-like effect; contributes to oedema in pregnancy)
Increases vascular tone - vasodilatory (increases skin warmth, flushing)
CVS: increases HDL, decreases LDL (cardioprotective in pre-menopausal women)
Stimulates prolactin secretion from anterior pituitary

Applied Aspects

Condition	Relevance
Menopause / estrogen deficiency	Osteoporosis, vaginal atrophy, hot flashes, cardiovascular risk increase, dyspareunia
Hormone replacement therapy (HRT)	Prevents osteoporosis and menopausal symptoms; must weigh risk of DVT, breast cancer, endometrial cancer
Breast cancer (~35%)	Estrogen-dependent tumors; treatment: oophorectomy, tamoxifen (ERα/β antagonist), aromatase inhibitors (letrozole, anastrozole)
Endometrial cancer	Unopposed estrogen (anovulation, HRT without progestogen) → hyperplasia → carcinoma
Gynecomastia	Increased E:androgen ratio from liver disease, drugs, tumors, obesity
Oral contraceptives	Exogenous estrogen (+ progesterone) suppresses FSH/LH via negative feedback → prevents ovulation; also thickens cervical mucus
Liver disease	Impaired estrogen degradation → hyperestrinism → gynecomastia, spider naevi, palmar erythema
PCOS	Relative estrogen excess from chronic anovulation; increased endometrial risk
Selective ERMs (SERMs)	Tamoxifen: agonist on bone/uterus, antagonist on breast; Raloxifene: agonist on bone, antagonist on breast and uterus

6. Testosterone - MOA, Findings, and Applied Aspects

Synthesis

Leydig cells of testes are the primary source (~95% in males)
Precursor: cholesterol (from LDL uptake or de novo synthesis)
Rate-limiting step: P-450scc (20,22-desmolase) converts cholesterol → pregnenolone (requires StAR protein for mitochondrial transport)
Pathway: Cholesterol → Pregnenolone → 17α-OH-pregnenolone → DHEA → Androstenediol → Testosterone (preferred delta-5 pathway in Leydig cells)
LH stimulates Leydig cell testosterone production via cAMP/PKA
Normal male plasma level: ~400-700 ng/dL; relatively constant from ages 25-70 years
Transport: bound to SHBG (44%), albumin (54%), free (2%)

Mechanism of Action

Genomic (Primary) Pathway:

Testosterone enters target cell
In some tissues (prostate, skin, seminal vesicles, epididymis): 5α-reductase converts testosterone → DHT (dihydrotestosterone) - DHT has ~30-50× higher biological activity than testosterone
DHT binds androgen receptor (AR) with ~100× higher affinity than testosterone
Testosterone or DHT-AR complex translocates to nucleus
Binds to androgen response elements (AREs) in promoter regions
Gene transcription → protein synthesis → specific cell functions (growth, development)

Intracrine Control:

Whether a tissue responds to testosterone or DHT depends on whether it expresses 5α-reductase
Some tissues (brain, adipose) express aromatase → convert testosterone → estradiol (effects via ER, not AR)
Some effects may be non-genomic (via adenylyl cyclase/PKA system)

Functions of Testosterone (Findings)

Pre-natal:

Virilization of the male external genitalia (via DHT)
Development of Wolffian ducts (vas deferens, seminal vesicles, epididymis)
Descent of testes

At Puberty:

Enlargement of testes, penis, prostate, seminal vesicles
Development of secondary sex characteristics: pubic/axillary/facial/body hair, male-pattern baldness (DHT)
Sebaceous gland stimulation (acne)
Deepening of voice (laryngeal growth)
Pubertal growth spurt (testosterone is converted to E₂ which causes epiphyseal fusion - later than in females)
Libido and sexual behaviour

In Adults:

Spermatogenesis: works with FSH on Sertoli cells; high intratesticular concentration required
Protein anabolism: marked muscle mass increase (much greater than estrogen)
Erythropoiesis: increases RBC production via EPO stimulation → higher Hb in males
Bone density: increases mineral density; closes epiphyses (weaker effect than E₂)
Inhibin (from Sertoli cells) and testosterone feed back negatively to suppress FSH and LH

Applied Aspects

Condition	Mechanism/Relevance
Hypogonadism	Primary (testicular failure → high LH/FSH) or secondary (pituitary/hypothalamic → low LH/FSH); treated with testosterone replacement
Benign prostatic hyperplasia (BPH)	DHT-driven; treated with 5α-reductase inhibitors (finasteride, dutasteride)
Prostate cancer	Androgen-dependent; treated with androgen deprivation therapy (GnRH agonists → desensitization; flutamide - pure AR antagonist that blocks nuclear binding)
5α-reductase deficiency	Autosomal recessive; 46,XY individuals born with female/ambiguous external genitalia but masculinize at puberty (testosterone itself virilizes internal structures)
Androgen insensitivity syndrome (AIS)	AR mutation; 46,XY with female phenotype; no AR response despite high testosterone
Anabolic steroid abuse	Suppresses GnRH/LH/FSH → testicular atrophy, azoospermia, gynaecomastia (aromatization), hepatotoxicity, polycythaemia, dyslipidaemia
Ageing male	Testosterone declines gradually after age 40-50 ("andropause"); symptoms include decreased libido, fatigue, reduced muscle mass, osteoporosis
Testosterone aging paradox	Plasma levels constant 25-70y, then slow decline; production rate and clearance rate both change

7. Infertility

Definition: Failure to achieve pregnancy after 12 months of regular, unprotected sexual intercourse (or 6 months if woman >35 years)

Prevalence: Affects ~15% of couples. Causes: male factor ~30-40%, female factor ~40-50%, combined/unexplained ~20%

Causes in Males

Pre-testicular (Endocrine/Hypothalamic-Pituitary):

Hypogonadotropic hypogonadism (low GnRH, LH, FSH) - Kallmann syndrome, pituitary tumours, hyperprolactinaemia
Exogenous androgen/anabolic steroid use (suppresses LH/FSH)

Testicular:

Varicocele (most common correctable cause - ~35% of infertile men)
Cryptorchidism (undescended testes - impairs spermatogenesis due to higher temperature)
Klinefelter syndrome (47,XXY) - hypergonadotropic hypogonadism
Orchitis (mumps, TB)
Chemotherapy/radiation
Genetic: Y-chromosome microdeletions (AZF regions), CFTR mutations

Post-testicular (Outflow/Functional):

Obstructive azoospermia: vasectomy, congenital bilateral absence of vas deferens (CBAVD - associated with CFTR mutation), infection-related block
Ejaculatory dysfunction: retrograde ejaculation (diabetes, prostate surgery)
Sperm function disorders: antibodies, poor motility, morphology defects

Causes in Females

Ovulatory Dysfunction (~25-30%):

PCOS (most common - anovulation from LH/FSH imbalance, hyperandrogenism)
Hyperprolactinaemia (inhibits GnRH → anovulation)
Hypothalamic amenorrhoea (excess exercise, low body weight, stress)
Premature ovarian insufficiency/failure
Thyroid disorders (hypothyroidism → elevated TRH → elevated prolactin)

Tubal/Peritoneal Factors (~30%):

Tubal occlusion from PID (Chlamydia, gonorrhoea most common)
Endometriosis (adhesions, impaired tubal motility, folliculogenesis)
Previous ectopic pregnancy/surgical damage

Uterine Factors (~10%):

Fibroids (submucous - distort cavity)
Asherman's syndrome (intrauterine adhesions post-curettage)
Congenital uterine anomalies (septate uterus)
Polyps

Cervical Factors:

Antisperm antibodies
Defective cervical mucus
Cervical stenosis

Investigations

Male Investigations

Semen analysis (WHO 2021 reference values):

Parameter	Lower Reference Limit
Volume	≥1.4 mL
Total sperm count	≥39 million/ejaculate
Concentration	≥16 million/mL
Total motility	≥42%
Progressive motility	≥30%
Normal morphology (Kruger strict)	≥4%
Vitality	≥54%

Hormonal profile: FSH, LH, testosterone, prolactin, thyroid function
Karyotype (if azoospermia/severe oligospermia)
Y-chromosome microdeletion analysis
Testicular ultrasound (varicocele, volume assessment with Prader orchidometer)
CFTR gene analysis (if CBAVD)
Testicular biopsy: obstructive vs. non-obstructive azoospermia

Note: Semen analysis alone cannot distinguish fertile from infertile men.

Female Investigations

Ovulatory Assessment:

Menstrual calendar (regular cycles suggest ovulation)
Mid-luteal serum progesterone (Day 21): >3-5 ng/mL suggests ovulation
LH urine kits (detect LH surge)
Anti-Müllerian hormone (AMH): reflects ovarian reserve (antral follicle count)
FSH, LH (Day 2-3), estradiol: elevated FSH = reduced ovarian reserve
Prolactin, TSH, androgens (if PCOS suspected)

Structural Investigations:

Pelvic 2D transvaginal ultrasound (TVS): antral follicle count, uterine anomalies, fibroids, ovarian cysts
Hysterosalpingography (HSG): tubal patency, uterine cavity shape (gold standard for outpatient tubal assessment)
Hysterosonography/Saline infusion sonography (SIS): uterine cavity evaluation
Laparoscopy + chromopertubation (gold standard for tubal and peritoneal factor - direct visualization with dye injection through cervix)
Hysteroscopy: intrauterine pathology (polyps, septa, adhesions)
MRI pelvis: detailed uterine/ovarian anatomy

Diagnostic Procedures Summary

Investigation	What it assesses
Semen analysis	Sperm count, motility, morphology
Mid-luteal P4	Confirms ovulation
AMH	Ovarian reserve
Day-3 FSH/LH/E₂	Pituitary and ovarian reserve
HSG	Tubal patency + uterine cavity
TVS	Pelvis, follicles, endometrium
Laparoscopy	Endometriosis, adhesions, tubal disease
Karyotype	Chromosomal causes
Testicular biopsy	Obstructive vs. non-obstructive azoospermia

Treatment

Male Infertility

Cause	Treatment
Hypogonadotropic hypogonadism	GnRH pump or gonadotropin (hCG + FSH) injections
Varicocele	Varicocelectomy (surgical or radiological embolization)
Obstructive azoospermia	Surgical sperm retrieval (PESA, TESA, TESE) + ICSI
Non-obstructive azoospermia	Micro-TESE + ICSI
Retrograde ejaculation	Alkalinization of urine + sperm retrieval, or sympathomimetics
Hyperprolactinaemia	Dopamine agonists (cabergoline, bromocriptine)
Antisperm antibodies	IUI or IVF/ICSI

Female Infertility

Cause	Treatment
Anovulation (PCOS)	Lifestyle modification (weight loss), clomiphene citrate (SERM - blocks E receptor, increases FSH), letrozole (aromatase inhibitor - now preferred first-line), gonadotropin injections, laparoscopic ovarian drilling
Hyperprolactinaemia	Cabergoline/bromocriptine
Hypothyroidism	Levothyroxine
Premature ovarian failure	Donor oocyte IVF
Tubal factor	Laparoscopic salpingostomy/fimbrioplasty; IVF (bypass tubes)
Endometriosis	Laparoscopic excision/ablation; IVF for severe cases
Uterine fibroids	Myomectomy (submucous)
Asherman's syndrome	Hysteroscopic adhesiolysis
Cervical factor	IUI (bypasses cervix)

Assisted Reproductive Technologies (ART)

Technique	Indication
IUI (Intrauterine insemination)	Mild male factor, cervical factor, unexplained
IVF (In vitro fertilisation)	Tubal disease, endometriosis, unexplained after failed simpler tx
ICSI (Intracytoplasmic sperm injection)	Severe male factor, obstructive/non-obstructive azoospermia
GIFT/ZIFT	Rarely used now
Donor oocyte IVF	Premature ovarian failure, poor ovarian reserve
Surrogacy	Absent uterus, recurrent implantation failure
Preimplantation genetic testing (PGT)	Recurrent miscarriage, chromosomal/monogenic disorders

Sources:

Morgan & Mikhail's Clinical Anesthesiology, 7th Ed. - Physiological changes in pregnancy (Table 40-1)
Costanzo Physiology, 7th Ed. - Parturition, Lactation, Hormonal contraception
Ganong's Review of Medical Physiology, 26th Ed. - Parturition, Lactation, Gynecomastia, Hormones and Cancer
Guyton & Hall Textbook of Medical Physiology - Estrogen functions, Progesterone, Ovarian hormones
Medical Physiology (Boron & Boulpaep) - Testosterone synthesis, Androgen receptor MOA, DHT, 5α-reductase, Intracrine control
Berek & Novak's Gynecology - Menstrual cycle physiology, Infertility diagnostic framework

Foeto placental maternal unit Explain

Finding Sources

Searching Images

fetoplacental unit steroid hormone synthesis estriol DHEA fetus placenta mother diagram

A pathophysiology diagram illustrating the integrative model of IGF-1 and mTOR signaling pathways in the maternal-placental-fetal unit. The visual is divided into three sections: Mother, Placenta, and Fetus. In the maternal circulation, increased levels of IGF-1, IGFBP-4, and Zinc (co-factor) are shown, alongside IGFBP-3, IGFBP-5, PAPP-A, and PAPP-A2. Within the placenta, IGF-1 interacts with the IGF-1 receptor (IGF-1R), triggering a signaling cascade through Akt (p-S473) to mTORC1. This pathway is regulated by AMPK-alpha (inhibited) and leads to the activation of S6K1, rpS6, and 4E-BP1, promoting protein synthesis. Placental PAPP-A is elevated, while nuclear activity shows DNA methylation of the IGF1 promoter affecting mRNA expression. The diagram illustrates that these molecular shifts increase placental area and nutrient transfer across the fetal-facing basal membrane into fetal capillaries. The cumulative effect, driven by preconceptional maternal supplementation (SQLNS), is indicated as enhanced fetal growth. The model specifically targets mechanisms in low-resource settings related to maternal nutritional status and fetal stunting.

This clinical photograph displays a gross pathological specimen of an intact fetoplacental unit following a first-trimester pregnancy loss or termination at approximately 13-14 weeks of gestation. The specimen is laid out on a green surgical drape. The placenta is a discoid, dark red-to-brown vascular mass with a visible chorionic plate and branching vessels. The umbilical cord is long, pale, and yellowish-white, showing characteristic twisting (coiling) and a marginal or eccentric insertion into the placental disc. The fetus is positioned with limbs extended; the facial area is obscured by a green privacy block. A key diagnostic feature is visible on the fetal left hand, which demonstrates syndactyly (webbing or fusion of digits), serving as a significant morphological marker for fetal anomaly screening. The skin of the fetus appears translucent, consistent with late first-trimester development. This image is relevant for medical students and clinicians studying fetal pathology, embryology, and first-trimester congenital malformations.

This clinical photograph shows an en bloc gross specimen of a fetoplacental unit following medical termination of pregnancy due to Williams-Beuren syndrome (WBS). The fetus is positioned in a supine/oblique view alongside the placenta. Key facial dysmorphisms characteristic of WBS are visible, including a bulbous nasal tip, a long philtrum, malar hypoplasia, a pointed chin, and prominent earlobes. The skin displays generalized erythema and areas of cyanosis/discoloration consistent with post-mortem changes. The umbilical cord is seen attached to the fetal abdomen and inserting centrally into the placenta. The placenta is dark reddish-purple with a glistening fetal surface (chorionic plate), demonstrating a normal branching vascular pattern (chorionic vessels). This image is educationally significant for medical genetics and obstetrics, illustrating the phenotypic manifestations of the 7q11.23 microdeletion in a second-trimester fetus.

A medical infographic illustrating steroid hormone synthesis in human males, featuring a healthcare worker in green scrubs with call-outs to specific cellular sites. The diagram focuses on two primary cell types: Adrenal cells (top-left) and Leydig cells (bottom-right). Both diagrams show the uptake of cholesterol from the bloodstream into the mitochondria, where it is converted to pregnenolone. In the Adrenal cell, pregnenolone is shown moving to the Smooth Endoplasmic Reticulum (S.E.R.) to be synthesized into cortisol and testosterone. In the Leydig cell, the pathway shows pregnenolone entering the S.E.R. specifically for testosterone production. A clock in the upper right corner suggests a circadian or temporal component to these endocrine processes. This illustration serves as an educational tool for understanding the pathophysiology and biochemical pathways of male steroidogenesis, highlighting the roles of mitochondrial and cytoplasmic organelles in hormone metabolism.

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Searching Images

placenta structure syncytiotrophoblast villous gas exchange nutrients fetus

Summary : This figure illustrates the mechanisms of placental transfer for monoclonal antibodies and small molecules from maternal to fetal circulation, highlighting the structural organization of the placenta and placental villi, and the cellular pathways involved in each type of transfer. illustration: # Placenta Structure : • Depicts a fetus connected to the placenta. • The placenta is shown in cross-section, with a focus on the placental villi. # Placental Villi : • Enlarged schematic of a placental villus. • Key cell types labeled: cytotrophoblast, syncytiotrophoblast (STB), fibroblast, fetal macrophage, fetal endothelial cell. • Maternal blood and fetal blood compartments are indicated. • Shows the arrangement of maternal blood in the intervillous space and fetal blood within capillaries. # Monoclonal Antibody Transfer : • Diagram shows maternal blood containing antibodies. • Antibodies cross the syncytiotrophoblast (STB) layer via FcRn (neonatal Fc receptor). • Antibodies move through the villous stroma and fetal endothelial cells to reach fetal blood. • Pathway is directional: maternal blood → STB (via FcRn) → villous stroma → fetal endothelium → fetal blood. # Small Molecule Transfer : • Diagram shows maternal blood containing small molecules. • Small molecules diffuse across the STB, villous stroma, and fetal endothelial cells. • Pathway is less specific, suggesting passive diffusion from maternal to fetal blood. # Analysis : • The figure visually distinguishes the receptor-mediated transfer of antibodies (via FcRn) from the less-specific, likely diffusion-based transfer of small molecules. • Structural barriers (STB, villous stroma, fetal endothelium) are highlighted as key checkpoints for both transfer types. • The illustration emphasizes the complexity and selectivity of placental transfer mechanisms, with antibody transfer being more regulated than small molecule transfer.

This physiological diagram illustrates the biomechanical contraction patterns of the rami chorii within the human placenta. The visual features a central trunk-like structure representing the main stem villi, from which approximately six to eight secondary cylindrical branches radiate outward. The surface of these structures exhibits a textured, ridged appearance consistent with placental villous morphology. Black arrows are superimposed on the image to indicate directional vectors of mechanical force. Each branch displays one or two arrows oriented along its longitudinal axis, pointing centrally toward the trunk and junctions. This represents the contractile movement of the stem villi, which is critical for regulating fetoplacental blood flow and maintaining intrauterine vascular resistance. The image is designed for advanced medical education in embryology, obstetrics, and placental physiology, demonstrating how dynamic architectural changes in the chorionic villi facilitate maternal-fetal exchange.

This medical illustration details the human placental anatomy and maternal-fetal interface across three views. On the left, a macro-level diagram shows a fetus in utero with the umbilical cord and placental attachment. Two inset panels provide microscopic structural detail. The upper right panel displays a cross-section of a Chorionic Villous, illustrating the exchange interface where fetal blood vessels are separated from the maternal blood space by three distinct layers: the syncytiotrophoblast, cytotrophoblast, and underlying stroma containing Hofbauer cells (placental macrophages). The lower right panel illustrates the layered Chorioamniotic Membranes. From the amniotic fluid inward, the layers are identified as the amniotic epithelium, the amnion (containing fetal macrophages), the chorion (containing maternal macrophages and extravillous trophoblasts), and the maternal decidua. The decidual layer is shown to be rich in diverse immune and stromal cells, including T cells, fibroblasts, placental bed giant cells, uterine Natural Killer (NK) cells, and dendritic cells. The diagram serves as an educational tool for understanding placental barrier composition and immune cell distribution at the maternal-fetal interface.

I now have rich content from multiple sources. Let me compile the comprehensive answer.

The Feto-Placental-Maternal Unit

The feto-placental-maternal unit (also called the fetoplacental unit or maternal-fetal-placental unit) is the concept that the fetus, placenta, and mother function as an integrated endocrine system during pregnancy. No single compartment can produce the full range of hormones required to maintain pregnancy - each one fills enzymatic gaps in the others. This concept is most elegantly illustrated by the collaborative synthesis of estrogens, and it also encompasses progesterone, hCG, hPL, and the CRH-based parturition clock.

Why the Concept Exists: Enzymatic Limitations

Compartment	What it LACKS	What it HAS
Placenta	17α-hydroxylase (C17,20-lyase) - cannot convert C21 steroids to C19 androgens (DHEA); lacks 16α-hydroxylase	Aromatase (CYP19), P450scc, 3β-HSD; can convert cholesterol → pregnenolone → progesterone; can aromatize androgens → estrogens
Fetal adrenal gland	3β-HSD (in the "fetal zone"); cannot make cortisol/progesterone well	Massive DHEAS production; 16α-hydroxylase (in liver)
Fetal liver	Aromatase	16α-hydroxylase (converts DHEA → 16α-OH-DHEAS)
Mother	n/a - contributes LDL cholesterol and receives/metabolizes hormones	Provides cholesterol substrate; processes estriol; produces cortisol

This is why the human placenta is called an "incomplete steroidogenic organ" - it requires fetal C19 androgens as obligate precursors for estrogen synthesis.

The Key Diagram

Fetoplacental-Maternal unit: fetal HPA axis, DHEAS, progesterone, estriol synthesis, oxytocin, CRH interplay

Component 1: Progesterone Synthesis

Progesterone is synthesized almost entirely by the placenta from maternal cholesterol.

Pathway

Maternal LDL cholesterol is taken up by the syncytiotrophoblast
Placental P450scc (cholesterol side-chain cleavage enzyme) converts cholesterol → pregnenolone
Placental 3β-HSD converts pregnenolone → progesterone

The placenta produces progesterone in large amounts, secretes most of it into the maternal circulation (smaller amounts go to the fetus). The fetus uses placental progesterone as a substrate for cortisol synthesis in its adrenal glands.

Fetal Role

The fetal adrenal fetal zone lacks 3β-HSD, so it cannot use pregnenolone to make progesterone or cortisol directly → it uses progesterone supplied by the placenta as a substrate for cortisol biosynthesis
Placenta → progesterone → fetal adrenal → cortisol (this is why adrenalectomy of the fetus does not affect placental progesterone)

Importance of Progesterone

Maintains uterine quiescence (inhibits gap junctions, inhibits CAP gene expression, inhibits prostaglandins)
Maintains the decidua
Until weeks 7-9, the corpus luteum (maintained by hCG) is the main source; after this the placenta takes over completely - the luteo-placental shift
Progesterone receptor antagonist mifepristone (RU-486) causes abortion before week 7 by blocking this support

Component 2: Estrogen Synthesis - The Classic Example of the Unit

Estrogen synthesis during pregnancy is the clearest demonstration of obligate cooperation between all three compartments.

Three Estrogens Produced

Estrogen	Predominates	Potency
Estradiol (E₂)	All trimesters	Highest (x12 estrone)
Estrone (E₁)	Early pregnancy	Intermediate
Estriol (E₃)	2nd and 3rd trimesters (dominant)	Lowest (~1/100 E₂)

Pathway A: Estradiol and Estrone Synthesis

Involves: Fetal adrenal + Placenta

Fetal adrenal (fetal zone)
    ↓ LH/ACTH stimulus
DHEAS (dehydroepiandrosterone sulfate)
    ↓ Placenta: sulphatase removes sulfate
DHEA
    ↓ Placenta: aromatase (CYP19)
ESTRONE + ESTRADIOL (released into maternal circulation)

Alternatively, the maternal adrenal provides DHEAS → sulfatase in placenta → DHEA → aromatized to E₁/E₂

Pathway B: Estriol Synthesis - The Three-Compartment Pathway

Estriol requires: Fetal adrenal + Fetal liver + Placenta - all three are obligatory.

Fetal adrenal (fetal zone)
    ↓ ACTH (from fetal pituitary)
DHEAS
    ↓ Fetal LIVER: 16α-hydroxylase
16α-OH-DHEAS
    ↓ Placenta: sulphatase
16α-OH-DHEA
    ↓ Placenta: aromatase (CYP19)
ESTRIOL (16-hydroxy-17β-estradiol)
    → Released into maternal and fetal circulation

Key points:

Estriol cannot be made from simple hydroxylation of estradiol - it requires the 16-hydroxylation step that only occurs in the fetal liver
The fetal adrenal gland (fetal zone) produces enormously large amounts of DHEAS - the fetal adrenal is proportionally larger than the adult adrenal at term
Maternal serum/urine estriol is a marker of feto-placental-maternal unit integrity: if it falls, it signals compromise of the fetus, placenta, or one of the enzymatic pathways
Estriol is only 1/100 the potency of estradiol but promotes uteroplacental blood flow as potently as other estrogens - this may explain its dramatic rise in the 3rd trimester

Why Estrogen Levels Rise So Dramatically in Pregnancy

Trimester	Dominant source of estrogens	Notes
1st trimester	Corpus luteum (maintained by hCG)	Before placenta matures
2nd-3rd trimester	Placenta + fetal adrenal zone	After luteo-placental shift; DHEAS production increases ~20-fold near term

Component 3: Human Chorionic Gonadotropin (hCG)

Secreted by the syncytiotrophoblast (trophoblast cells of the developing placenta)
Begins 8 days after ovulation (before the next expected period)
α subunit is identical to FSH, LH, TSH; β subunit is unique (longer than LH β-subunit, contains extra C-terminal peptide)
Function: acts on LH receptors on corpus luteum cells → prevents regression → corpus luteum continues producing E₂ and progesterone ("rescue of the corpus luteum")
Levels: rise exponentially in 1st trimester, peak at ~8-12 weeks (~100,000 mIU/mL), then decline as placenta takes over steroid synthesis
Clinical use: basis of pregnancy test (detectable in urine 9 days after ovulation); serum β-hCG monitors ectopic pregnancy, molar pregnancy, choriocarcinoma
hCG also has weak TSH-like activity → mild physiological hyperthyroidism in the 1st trimester (morning sickness partly attributed to this)

Component 4: Human Placental Lactogen (hPL) / Human Chorionic Somatomammotropin

Secreted by syncytiotrophoblast; structure similar to growth hormone and prolactin
Levels rise throughout pregnancy proportional to placental mass
Functions:
- Metabolic shift: acts as a growth hormone analogue on maternal tissues → promotes insulin resistance in the mother → diverts glucose to the fetus (the fetus is a "glucose thief")
- Promotes lipolysis in the mother → free fatty acids used by mother for energy while glucose is spared for fetus
- Promotes breast development (with prolactin)
- May stimulate fetal growth (IGF-1 mediated)
Clinical significance: hPL-driven insulin resistance is the main cause of gestational diabetes mellitus

Component 5: The CRH-Based "Placental Clock" and the Fetal HPA Axis

This is the mechanism by which the fetus effectively "picks the time to be born":

Fetal hypothalamus → CRH (increases with gestational age)
    ↓
Fetal anterior pituitary → ACTH
    ↓
Fetal adrenal cortex → Cortisol + DHEAS
    ↓                              ↓
Cortisol feeds back to       DHEAS enters placenta
PLACENTA (positive            → aromatised to estrogens
feedback - unlike
hypothalamus)
    ↓
Placenta secretes MORE CRH
(amplifying loop)
    ↓
More cortisol → matures fetal lung surfactant
+ Shifts E:P ratio → promotes prostaglandins → uterine contractions

Key facts:

Placental CRH production is upregulated (not suppressed) by fetal cortisol - the opposite of hypothalamic feedback - creating a positive amplifying loop
CRH-binding protein (CRH-BP) keeps most CRH inactive; near term CRH-BP falls → free active CRH rises
Some authorities propose a "placental clock" set early after implantation by the rate of CRH gene expression, determining gestational length
The 11β-HSD-2 enzyme in the syncytiotrophoblast converts maternal cortisol → inactive cortisone, protecting the fetus from high maternal cortisol levels. Its impairment in hypoxia/preeclampsia may cause IUGR and fetal programming of adult disease.

Component 6: Placental Structure Enabling the Unit

The syncytiotrophoblast (the outermost layer bathed in maternal blood) is the metabolically active zone:

Single multinucleate layer in direct contact with maternal blood in the intervillous space
No MHC class I antigens → does not trigger maternal immune rejection
Site of: steroid synthesis, hCG/hPL secretion, nutrient/gas exchange, immunoglobulin transfer (FcRn receptor)

Transfer across the placenta:

Substance	Mechanism
O₂, CO₂, water	Diffusion
Glucose	Facilitated diffusion (GLUT transporters)
Amino acids	Active transport
Fatty acids, fat-soluble vitamins	Diffusion
IgG antibodies	Receptor-mediated endocytosis (FcRn - neonatal Fc receptor) → passive immunity to neonate
Maternal cortisol	Mostly inactivated by 11β-HSD-2 in syncytiotrophoblast
Drugs, alcohol, many viruses (TORCH)	Diffusion (clinical concern)

Summary: Who Does What

Hormone/Product	Made by	Requires input from	Function
Progesterone	Placenta	Maternal LDL cholesterol	Uterine quiescence; decidua; fetal adrenal substrate
Estradiol (E₂)	Placenta (aromatase)	Fetal adrenal DHEAS	Uterine growth; cervical ripening; breast development
Estriol (E₃)	Placenta (aromatase)	Fetal adrenal DHEAS + fetal liver 16α-OH	Uteroplacental blood flow; marker of fetal well-being
hCG	Trophoblast	-	Rescues corpus luteum; maintains E₂/P4 in 1st trimester
hPL	Trophoblast	-	Maternal insulin resistance; fetal nutrition priority
Fetal cortisol	Fetal adrenal	Placental progesterone as substrate	Lung maturation; parturition trigger
Placental CRH	Syncytiotrophoblast	Fetal cortisol (positive feedback)	Placental clock; parturition cascade

Clinical Significance

Clinical Point	Mechanism
Pregnancy test	Detects hCG in urine from day 9 post-ovulation
1st trimester bleeding / threatened miscarriage	Serial β-hCG and progesterone levels monitored
Unconjugated estriol (uE₃) in triple/quadruple screen	Low uE₃ suggests placental insufficiency, fetal adrenal suppression, or Down syndrome (T21 - low)
Down syndrome screening	↑hCG, ↓AFP, ↓uE₃ → "triple test" for T21
Gestational diabetes	hPL-driven insulin resistance
Molar pregnancy / choriocarcinoma	Extremely high hCG levels from abnormal trophoblast proliferation
Antenatal corticosteroids (betamethasone)	Given to mother when preterm birth threatened → crosses placenta → accelerates fetal lung surfactant maturation (mimics fetal cortisol effect)
Fetal distress / IUGR	Impaired 11β-HSD-2 → excess maternal cortisol reaches fetus → growth restriction
Preterm birth	Premature activation of fetal HPA axis → early DHEAS surge → premature estrogen rise → early onset of parturition cascade

Sources:

Creasy & Resnik's Maternal-Fetal Medicine - Fetal HPA axis, DHEAS pathway, estriol synthesis, placental CRH clock, progesterone role
Costanzo Physiology, 7th Ed. - hCG, corpus luteum rescue, early pregnancy events, luteo-placental shift
Medical Physiology (Boron & Boulpaep) - Progesterone synthesis by placenta, estriol pathway
Tietz Textbook of Laboratory Medicine - hCG kinetics, estriol as marker of fetoplacental integrity

This is a shared conversation. Sign in to Orris to start your own chat.